IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?

Seth Bilazarian and Chris Cannon discuss the role of ezetimibe in secondary prevention and whether super-low LDL-C levels are the way to go. theheart.org on Medscape

Source: theHeart.org - December 1, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news